Pharmacist comparing drug packaging
The Central Drugs Standard Control Organisation (CDSCO) in India is initiating measures to address the proliferation of confusing brand name extensions for pharmaceutical products. This move is aimed at reducing ambiguity and potential errors in medication selection, thereby enhancing patient safety and streamlining the pharmaceutical market.
Historically, pharmaceutical companies have utilized similar-sounding or visually alike brand names for different drugs, or extended existing brand names with suffixes for variations of the same medicine. This practice has led to significant confusion among healthcare professionals and patients alike, increasing the risk of medication errors. The CDSCO’s intervention seeks to standardize branding conventions and ensure that drug names clearly differentiate between distinct therapeutic agents or formulations.
This regulatory action is expected to have a notable impact on pharmaceutical manufacturers, requiring them to review and potentially revise their branding strategies. The objective is to foster a more transparent and safer pharmaceutical landscape in India, aligning with global best practices in drug regulation and patient welfare. The specifics of the new guidelines and their enforcement timeline are anticipated to be released shortly.
About the Author
